Serum Markers and Clinical Response to Golimumab in Rheumatoid Arthritis
Author Information
Author(s): Visvanathan Sudha, Rahman Mahboob U, Keystone Edward, Genovese Mark, Klareskog Lars, Hsia Elizabeth, Mack Michael, Buchanan Jacqui, Elashoff Michael, Wagner Carrie
Primary Institution: Centocor Research and Development, Inc.
Hypothesis
The study aims to identify serum markers modulated by golimumab treatment that are associated with clinical response in rheumatoid arthritis patients.
Conclusion
Golimumab treatment leads to distinct changes in serum protein profiles that correlate with clinical response measures in rheumatoid arthritis patients.
Supporting Evidence
- Golimumab treatment resulted in significant decreases in serum proteins compared to placebo.
- Distinct biomarker profiles were observed in ACR 20 and ACR 50 responders.
- Some biomarkers were associated with multiple clinical response measures.
- The predictive values of the biomarker panel were stronger than C-reactive protein alone.
Takeaway
This study looked at blood markers in people with rheumatoid arthritis to see how they change when treated with a medicine called golimumab, helping doctors understand who might respond best to the treatment.
Methodology
Patients were randomly assigned to receive different treatments, and serum samples were collected and analyzed for various biomarkers at multiple time points.
Limitations
The small size of the training dataset may limit the reproducibility of findings in the larger test dataset.
Participant Demographics
The study included 336 patients with active rheumatoid arthritis, with a mix of treatment groups and demographics.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website